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A correlation between excess mortality from myocardial infarctions (MI) and schizophrenia
has already been established. What remains unclear is whether the initial communication
between the treating doctor and the corresponding patient contributes to this excess
mortality.
Aim
The aim of this study is to investigate whether a patient with schizophrenia receives the
same offers for examination and treatment following a MI compared to a psychiatric healthy
control (PHC).
Methods
This cohort study includes patients diagnosed with schizophrenia at the time of their first MI
(n = 47) in the years between 1995–2015 matched 1:2 to psychiatric healthy MI patients on
gender, age and year of first MI. All existing hospital files for the 141 patients were thor-
oughly reviewed and the number of offered and accepted examinations and treatments
were extracted for comparisons between the two groups.
Results
In general patients with schizophrenia were less likely to be offered and accept examination
and at the same time be offered and accept treatment as compared to PHCs (p<0.01). In
addition, there was a statistical trend towards patients with schizophrenia being more likely
to decline examination (p = 0.10) and decline treatment (p = 0.09) compared to PHCs, while
being offered examination and being offered treatment both contributed statistically insignif-
icantly to the overall discrepancy between the two patient groups.
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Conclusions
Being diagnosed with schizophrenia limits the treatment received following a first MI com-
pared to PHCs. However, we are unable to pinpoint, whether Physician bias, patient’s
unwillingness to receive health care or both contribute to the excess mortality seen in these
comorbid patients.
Introduction
An increasing amount of literature has confirmed a positive correlation between mental disor-
ders and increased mortality [1,2], particularly in patients with schizophrenia [3–9]. The aver-
age age of death in patients with schizophrenia independent of self-harm has decreased over
the past three decades while it has increased in the general population. This pattern results in
an increased gap in life expectancy between the populations [10]. The excess mortality can be
linked to an increased prevalence of cardiovascular diseases (CVD) in patients with schizo-
phrenia [11–14]. In particular, a strong correlation between myocardial infarctions (MI) and
schizophrenia has been established [2,15,16]. The increased prevalence of CVD can be
explained by the unhealthy lifestyle of this population consisting of excessive smoking and
drinking, an unbalanced diet together with the use of antipsychotic drugs which leaves the
patient at greater risk of developing CVD [7,17,18].
It has already been established that patients with schizophrenia undergo fewer cardiac pro-
cedures compared to the general population [4,19,20]. However, it remains unclear whether
these patients receive the same offers of examination and treatment by their doctor compared
to the psychiatric healthy control (PHC) population. This study focuses on the four-stage pro-
cess from initial admission following MI including offer of examination, accept of examina-
tion, offer of treatment and finally the accept of treatment which leads to the overall outcome
of completing all four stages with positive outcome (Fig 1). Thus, the aim of this study is to
investigate the number of patients who completes all four stages and accepts treatment in the
final stage. Secondary analyses will cover the relative role played by the doctor and the patient
following admission for MI.
Methods
Study design
This cohort study investigates received cardiac treatment in patients with schizophrenia com-
pared to a PHC population through the process of reviewing the patients’ hospital files and ana-
lysing the initial communication between the doctor and patient after admission following MI.
Data collection
All persons born in or permanently residing in Denmark are a part of the Danish Civil Regis-
tration System [21]. Each person is assigned a 10-digit “Central Person Register” (CPR) num-
ber, facilitating the unique linkage between different national registers, the local patients
administrative system and the psychiatric patient database [22]. The different registers include
information on gender, age and patient hospital files including date of hospitalisation, dis-
charge diagnosis and procedures performed during the admission. The initial search for
patients with an ICD-10 MI diagnosis (I21) including both ST elevation MI (STEMI) and non
ST-elevation MI (NSTEMI) in the period of 1995–2015 resulted in a list of 12.902 people, all
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registered as residents of Northern Denmark. This list was cross-linked with an ICD-10
schizophrenia diagnosis (F20) resulting in a final list of 47 patients diagnosed with schizophre-
nia at the time of their first MI. Each of the 47 patients was assigned two PHC controls,
matched on year of first MI, gender and age. All existing hospital files for the 141 patients were
thoroughly reviewed and relevant data was collected in electronic case report forms. The data
were analysed anonymously. The study was authorized by the Danish Data Protection Agency
(2008-58-0028) and patient identification through registers ware approved by the Danish
Health Data Authority (FSEID-00002258).
Statistical analysis
Descriptive statistics are presented as either means and standard deviations or frequencies and
percentages as appropriate. The descriptive data includes gender, age, BMI, smoking status, his-
tory of diabetes, hypercholesterolemia, hypertension and family predisposition for CVD. It is a
standard procedure to include family predisposition during admission for CVD. The primary
and secondary outcomes were dichotomous and included: if the treating physician offered
examination and treatment to the patient and if the patient accepted the offer made. The sec-
ondary subgroup analyses only included susceptible patients, i.e. only patients who were offered
examination were included in the subsequent analyses, and only patients who accepted exami-
nation were included in the analyses on treatment and so forth. All patients were included in
the primary analysis testing how many patients actually completed all four stages with positive
outcome (Fig 1). Finally, we compared what type of examination and treatment was offered.
The outcomes and descriptive data were compared between the two groups of patients using a
t-test for continuous data and Fisher’s exact test for dichotomous and categorical data. Missing
data was assessed in each variable separately and each patient contributed to results concerning
variables where his or her data were non-missing. All analyses were performed using Stata sta-
tistical software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: Sta-
taCorp LP). P-value less than 0.05 was considered statistically significant.
Results
Demographics
The study population comprised 141 patients diagnosed with a first myocardial infarction dur-
ing the time period 1995–2015; among these, 47 patients also had a diagnosis of schizophrenia
Fig 1. Above; illustrates the four stages in the pretreatment process used for the secondary subgroup
analyses. In each of the four stages we investigate whether examination and treatment was offered by the
doctor and accepted by the corresponding patient following a first MI. Patients were only considered
susceptible to a stage if they completed the previous stage with positive outcome, otherwise they were
removed from further analysis. Below; illustrates the pretreatment process used for the primary analysis, in
which all stages are truncated into one.
https://doi.org/10.1371/journal.pone.0189289.g001
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at the time of their first MI. The results obtained on demographics and clinical characteristics
for the different populations are shown in Table 1. Patients with schizophrenia had a statisti-
cally significant higher prevalence of smoking (p: 0.03) and a lower familial predisposition for
CVD (p: 0.02) compared to their matched controls.
Examination and treatment
Data on three patients with schizophrenia were partly missing because of incomplete patient
journals. The first patient was lost after stage 1, while two other patients were lost after stage 3.
None of the PHCs had incomplete journals. The primary analysis accounted only patients
with complete datasets.
Patients with schizophrenia were statistically significantly less likely to be offered and accept
examination and at the same time be offered and accept treatment as compared to PHCs
(p<0.01) as shown in Table 2. However, when analysing each stage individually, none of the
secondary results were statistically significant (Table 2), though, a trend was found for the dif-
ference in the proportions of accepted examinations (p: 0.10) as well as accepted treatments (p:
0.09) between the two groups with a 100% acceptance among controls for both outcomes.
The types of examination offered and its distribution were as following: CAG (schiz: 91.1%,
PHC: 97.9%) CT-CAG (schiz: 0, PHC: 1.1%) and exercise-ECG (schiz: 8.9%, PHC: 1.1%).
CAG was the predominant type of examination offered to both populations, with higher
occurrence among the controls, however, more patients with schizophrenia were offered exer-
cise-ECG, this difference was of statistical significance (p: 0.04). Similarly, the types of treat-
ment offered and the distribution were: medication (schiz: 14.6%, PHC: 15.4%), PCI (schiz:
82.9%, PHC: 75.8) and CABG (schiz: 2.4%, PHC: 8.8%), however, this difference in type distri-
bution was not statistical significant.
Discussion
Despite each step in the four-step processes being of no statistical significance when analysed
individually, they as a whole contribute to the primary outcome of less cardiac treatment
received in the schizophrenia population. Therefore, it seems that each step from initial
Table 1. Demographics of the study population.
Schizophrenia, n (sd) PHC, n (sd) P-value Available data*
Age, years 53.4 (12.0) 54.1 (12.0) 0.76 (47,93)
BMI, kg/(m2) 28.9 (6.7) 27.5 (5.3) 0.24 (32,74)
Schizophrenia, n (%) PHC, n (%) P-value Available data
Male 32 (68.1) 65 (69.1) 1.00 (47,94)
Smoking 0.03 (43,89)
! Active 31 (73.8) 45 (50.6)
! Never 7 (16.7) 20 (22.5)
! Previous 4 (9.5) 24 (27.0)
Diabetes 5 (11.6) 13 (14.6) 0.79 (43,89)
Hypercholesterolemia 15 (35.7) 36 (40.0) 0.70 (42,90)
Hypertension 15 (36.6) 35 (38.9) 0.85 (41,90)
Family predisposition for CVD 10 (26.3) 43 (50.0) 0.02 (38,86)
PHC, psychiatric healthy control
* number of available patients in the group of patients with schizophrenia and PHC, respectively. The values indicate the number of susceptible patients
minus the number of patients with missing data because of incomplete patient journals.
https://doi.org/10.1371/journal.pone.0189289.t001
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admission to final decision contributed to the lower rate of treatment in the schizophrenia
population. However, without statistical significance we are unable to pinpoint, whether Physi-
cian bias, patient’s unwillingness to receive health care or both contribute to the excess mortal-
ity seen in patients with Schizophrenia and first MI. Apart from the primary outcome being of
significant difference, we also found a dissimilarity in the type of procedures offered between
the populations. Patients with schizophrenia were less likely to be offered invasive CAG and
received more offers of exercise-ECG, which was in contrast to the controls who predomi-
nantly received offers of CAG. This is in accordance to previous studies that have concluded
patients with schizophrenia to have a lower rate of invasive cardiac procedures performed,
amongst these, CAG [23–26]. However, for treatments, we did not find any statistically signifi-
cant difference between the populations.
The difference in the offered cardiac procedures, although of no statistical significance,
could possibly be explained by either the severity of MI and/or physician bias. The severity of
MI was not accounted for in our study but was however concluded to be equal in a population
with schizophrenia compared to the general population in a previous study [27]. Physician
bias originates in the stigma around mentally ill patients, not only seen in the community but
also in the hospital settings [20]. It can be either intentional or unintentional and may result in
a failure to act [28]. When applied to our study this implies a failure to offer treatment to
patients despite the necessity for it. The clinical manifestation of schizophrenia may be seen as
a complication for postoperative care and influence final decisions of cardiac procedures fol-
lowing a MI. Thus, these decisions may be based on tacit assumptions rather than standard
guidelines based on medical outcomes. Three of the patients in our study population with
schizophrenia reported that they had previously visited the hospital complaining of typical
chest pain but where sent home without examination. This is further strengthened by one
study that found that patients with schizophrenia only receive care when their symptoms
become severe enough [29] and that doctors tend to have a more negative attitude towards
comorbid schizophrenia patients [30].
We also found a statistically trend of patients with schizophrenia being more likely to
decline offers of both examination and treatment compared to the general population. This
trend may be owed to the patients unwillingness to cooperate [31] or lack of insight to their ill-
ness and consequently failure to understand the importance of either being examined or
treated [32,33]. This is supported by the reasons to which the patients with schizophrenia in
our study declined offers. Some patients reported they did not ‘need’ the examination or
Table 2. Results on examination and treatment. Primary results show the fraction of all patients who completed all four stages of the pretreatment process
with positive outcome. Secondary results show the fraction of susceptible patients who completed each stage of the pretreatment process with positive out-
come. We considered a patient susceptible for a stage in the pretreatment process if the patient had completed the previous stage with positive outcome.
Schizophrenia, n (%) PHC, n (%) P-value Available data*
Primary analysis
Pretreatment completed with positive outcome 37 (84.1) 92 (97.9) <0.01 (44,94)
Secondary analyses
Examination was offered (stage 1) 45 (95.7) 92 (97.9) 0.60 (47,94)
Examination was accepted (stage 2) 42 (95.5) 92 (100.0) 0.10 (44,92)
Treatment was offered (stage 3) 41 (97.6) 92 (100.0) 0.31 (42,92)
Treatment was accepted (stage 4) 37 (94.9) 92 (100.0) 0.09 (39,92)
PHC, psychiatric healthy control
* number of available patients in the group of patients with schizophrenia and PHC, respectively. The values indicate the number of susceptible patients
minus the number of patients with missing data because of incomplete patient journals.
https://doi.org/10.1371/journal.pone.0189289.t002
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treatment while others failed to turn up for the appointment, which was also considered a
decline. The failure to turn up can be owed to the negative symptoms patients with schizophre-
nia can experience, which amongst other symptoms includes lack of interest and motivation to
pursue a goal [34,35]. Furthermore, we found no difference in offers of examination and the
distribution of different treatment types. These contradictive results may be explained by the
small population size in our study.
This study also investigated other characteristics of the study population (Table 1) to get a
general idea of whether patients with schizophrenia were somatically sicker than their controls.
We expected to find a correlation, which could help explain the hypothesised fewer offers
being made to the population with schizophrenia. However, we only found two significant dif-
ferences between the populations; patients with schizophrenia were more likely to be smokers
and had a lower familial predisposition to CVD. The higher tendency of smoking in patients
with schizophrenia has previously been established [36]. Moreover, we assume that the low
familial predisposition to CVD is owed to the patient’s unawareness of family medical history
and has thus been reported wrongfully and not accounted for as a risk factor. However,
patients with schizophrenia may also have higher risk of MI due to smoking and, conse-
quently, familial CVD may be less relevant to them. Furthermore, patients with schizophrenia
were less likely to be in treatment for diabetes, hypercholesterolemia and hypertension at the
time of a first MI. This difference did not reach statistical significance but is in accordance
with the CATIE study [37] that concluded low treatment for diabetes, hypercholestemia and
hypertension in a population with schizophrenia. The results found in our study points to
under-treatment of the patients with schizophrenia since many studies have concluded these
patients to have an increased blood glucose level, a higher prevalence of diabetes type 2 [38–
40] and hypercholesterolemia [39] compared to the general population.
Despite the differences in each step of the pre-treatment procedure not being statistically
significant, our data show a clear difference between the two populations in healthcare and
that the doctor-patient interaction may help explain the trend of fewer cardiac procedures
offered and received by the patients with schizophrenia, confirming our main hypothesis.
Clinical application
Patients with schizophrenia belong to a vulnerable group prone to comorbidity that requires
special attention. In order to decrease the gap in excess mortality some changes should be
implemented in the healthcare system upon initial admission. Firstly, there is a mismatch
between the somatic and mental healthcare that needs to be addressed. A more integrated
approach and improved collaboration between these two fields in medicine could result in ear-
lier detection of disease that in turn would lead to better prognosis. Secondly, the handling of
the patient with schizophrenia by the treating doctor needs to be reformed. It is important that
the health care provider is aware of the limits of dealing with a double diagnosed patient, it
also important to educate health care personnel on the issue of unintentional bias that may
occur. A more personalized approach towards the patient would perhaps make the patient
more susceptible to the health care system and more willing to cooperate. Ultimately, routine
check-ups along with better guidance to a healthier lifestyle could decrease the incidence of
CVD in the schizophrenia population.
Conclusion
The results in the present study suggests that there is a significant difference in the proportion
of patients with schizophrenia who are being offered and accepts examination and at the same
time being offered and accepts treatment in comparison to a population of psychiatric healthy
Myocardial infarction and schizophrenia
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controls. However, we cannot pinpoint at which stage in the pretreatment process this discrep-
ancy emerges, as all stages contribute a little, though the results of the analyses concerning the
individual stages are statistically insignificant. Furthermore, the study revealed a trend towards
patients with schizophrenia being more likely to decline offers made by the treating doctor for
both examination and treatment. However, we suspect that the reason for these differences is a
combination of physician bias and the patient’s willingness to cooperate and understand the
extent of their somatic disease, where the latter plays a larger role. A more integrated somatic
and mental hospital system and routine screenings could contribute to reduce the excess mor-
tality from MI in patients with schizophrenia.
Limitations
Greater statistical significance could have been reached with a larger sample population. How-
ever, due to the study being limited to the North Denmark Region, no more patients were
available. Furthermore, we did not match our population for social class, which may have
affected our results, though healthcare in Denmark is free and equally available for all perma-
nent residents of Denmark.
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